Deborah Morosini - Dec 15, 2021 Form 4 Insider Report for Prelude Therapeutics Inc (PRLD)

Role
EVP, Chief of Clinical Affairs
Signature
/s/ Krishna Vaddi, Attorney-in-Fact
Stock symbol
PRLD
Transactions as of
Dec 15, 2021
Transactions value $
-$37,368
Form type
4
Date filed
12/17/2021, 04:20 PM
Previous filing
Nov 18, 2021
Next filing
Feb 17, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PRLD Common Stock Options Exercise $5.7K +3.02K +679.28% $1.89 3.46K Dec 15, 2021 Direct
transaction PRLD Common Stock Options Exercise $331K +25.7K +743.79% $12.85 29.2K Dec 15, 2021 Direct
transaction PRLD Common Stock Sale -$374K -28.8K -98.48% $13.00 444 Dec 15, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRLD Employee Stock Option (right to buy) Options Exercise $0 -3.02K -69.77% $0.00 1.31K Dec 15, 2021 Common Stock 3.02K $1.89 Direct F2
transaction PRLD Employee Stock Option (right to buy) Options Exercise $0 -24.9K -25% $0.00 74.6K Dec 15, 2021 Common Stock 24.9K $12.85 Direct F3
transaction PRLD Employee Stock Option (right to buy) Options Exercise $0 -882 -0.45% $0.00 195K Dec 15, 2021 Common Stock 882 $12.85 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The stock option is fully vested.
F3 The stock option vests as to 25% of the total shares monthly beginning on September 24, 2021, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date.
F4 The stock option vests as to 25% of the total shares monthly beginning on July 27, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date.